RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE
Press release of JSC "BAYER"
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2017-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Online Access: | https://www.rpcardio.com/jour/article/view/1543 |
| _version_ | 1827793095658307584 |
|---|---|
| author | статья Редакционная |
| author_facet | статья Редакционная |
| author_sort | статья Редакционная |
| collection | DOAJ |
| description | Press release of JSC "BAYER" |
| first_indexed | 2024-03-11T18:12:41Z |
| format | Article |
| id | doaj.art-dd9f8c3a7b2c449089dbcfc8502ec068 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-03-11T18:12:41Z |
| publishDate | 2017-11-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-dd9f8c3a7b2c449089dbcfc8502ec0682023-10-16T11:32:12ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532017-11-011351398RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASEстатья РедакционнаяPress release of JSC "BAYER"https://www.rpcardio.com/jour/article/view/1543 |
| spellingShingle | статья Редакционная RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE Рациональная фармакотерапия в кардиологии |
| title | RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE |
| title_full | RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE |
| title_fullStr | RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE |
| title_full_unstemmed | RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE |
| title_short | RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE |
| title_sort | rivaroxaban of the bayer company significantly by 24 reduces the risk of stroke cardiovascular death and myocardial infarction in patients with chronic ischemic heart disease or peripheral arterial disease |
| url | https://www.rpcardio.com/jour/article/view/1543 |
| work_keys_str_mv | AT statʹâredakcionnaâ rivaroxabanofthebayercompanysignificantlyby24reducestheriskofstrokecardiovasculardeathandmyocardialinfarctioninpatientswithchronicischemicheartdiseaseorperipheralarterialdisease |